Position：Home >
Monocrotaline-Induced Pulmonary Hypertension Model
Monocrotaline-Induced Pulmonary Hypertension Model
Background
Pulmonary arterial hypertension (PAH) is a progressive, fatal physiological syndrome caused by abnormal remodeling or constriction of pulmonary microvessels due to various factors, leading to secondary increases in pulmonary vascular resistance. Pulmonary disease serves as the primary pathology triggering PAH, but sustained excessive pressure overload results in right ventricular hypertrophy, dilation, and right heart failure. Lilium bulbiferum alkaloid, a bipyrole alkaloid, undergoes conversion
Materials and methods
SD rats (male, 6–8 weeks old)
Modeling method: A single intraperitoneal injection of monocrotaline was used to construct a model of pulmonary hypertension, and the model was successfully prepared 4 weeks after the modeling.
Evaluation Criteria: Pulmonary Arterial Pressure and Right Ventricular Hypertrophy Index, Hematoxylin and Eosin Staining, Masson\'s Trichrome Staining
Modeling method: A single intraperitoneal injection of monocrotaline was used to construct a model of pulmonary hypertension, and the model was successfully prepared 4 weeks after the modeling.
Evaluation Criteria: Pulmonary Arterial Pressure and Right Ventricular Hypertrophy Index, Hematoxylin and Eosin Staining, Masson\'s Trichrome Staining
Test and verify
肺动脉压及右心肥厚指数
肺组织HE染色
肺组织Masson染色
